Is (1,3)-β-D-glucan Useless to Guide Antifungal Therapy in ICU?

Overview

Journal Intensive Care Med

Specialty Critical Care

Date 2022 Jun 30

PMID 35771251

Authors

Anahita Rouze

Angel Estella

Jean-Francois Timsit

Affiliations

Soon will be listed here.

Citing Articles

Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions.

Novy E, Esposito M, Debourgogne A, Roger C J Fungi (Basel). 2025; 11(2).

PMID: 39997386 PMC: 11856068. DOI: 10.3390/jof11020091.

The (1,3)-β-D-glucan use for invasive candidiasis diagnosis in non-neutropenic critically ill patients: a prospective cohort study.

Tlili B, Trifi A, Kallel A, Mehdi A, Seghir E, Messaoued L Tunis Med. 2025; 102(12):1004-1008.

PMID: 39748684 PMC: 11770794. DOI: 10.62438/tunismed.v102i12.5254.

The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document.

Candel F, Salavert M, Canton R, Del Pozo J, Galan-Sanchez F, Navarro D Crit Care. 2024; 28(1):440.

PMID: 39736683 PMC: 11687037. DOI: 10.1186/s13054-024-05224-3.

Comparison of β-1-3-D-Glucan and Mannan Biomarker Assays with Serological Tests for the Diagnosis of Candidemia.

Eades C, Bakri A, Lau J, Moore C, Novak-Frazer L, Richardson M J Fungi (Basel). 2023; 9(8).

PMID: 37623584 PMC: 10455369. DOI: 10.3390/jof9080813.

Efficient Recovery of Candida auris and Five Other Medically Important Species from Blood Cultures Containing Clinically Relevant Concentrations of Antifungal Agents.

Posteraro B, Menchinelli G, Ivagnes V, Cortazzo V, Liotti F, Falasca B Microbiol Spectr. 2023; :e0410422.

PMID: 36715537 PMC: 10100679. DOI: 10.1128/spectrum.04104-22.

References

Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M . Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014; 40(9):1303-12. PMC: 4147247. DOI: 10.1007/s00134-014-3408-3. View

Leroy O, Bailly S, Gangneux J, Mira J, Devos P, Dupont H . Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care. 2016; 6(1):2. PMC: 4705061. DOI: 10.1186/s13613-015-0103-7. View

Clancy C, Nguyen M . Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013; 56(9):1284-92. DOI: 10.1093/cid/cit006. View

Dupont H, Mahjoub Y, Chouaki T, Lorne E, Zogheib E . Antifungal Prevention of Systemic Candidiasis in Immunocompetent ICU Adults: Systematic Review and Meta-Analysis of Clinical Trials. Crit Care Med. 2017; 45(11):1937-1945. DOI: 10.1097/CCM.0000000000002698. View

Timsit J, Azoulay E, Schwebel C, Charles P, Cornet M, Souweine B . Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial. JAMA. 2016; 316(15):1555-1564. DOI: 10.1001/jama.2016.14655. View

Haydour Q, Hage C, Carmona E, Epelbaum O, Evans S, Gabe L . Diagnosis of Fungal Infections. A Systematic Review and Meta-Analysis Supporting American Thoracic Society Practice Guideline. Ann Am Thorac Soc. 2019; 16(9):1179-1188. DOI: 10.1513/AnnalsATS.201811-766OC. View

Dupuis C, Le Bihan C, Maubon D, Calvet L, Ruckly S, Schwebel C . Performance of Repeated Measures of (1-3)-β-D-Glucan, Mannan Antigen, and Antimannan Antibodies for the Diagnosis of Invasive Candidiasis in ICU Patients: A Preplanned Ancillary Analysis of the EMPIRICUS Randomized Clinical Trial. Open Forum Infect Dis. 2021; 8(3):ofab080. PMC: 8002176. DOI: 10.1093/ofid/ofab080. View

Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele J . ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019; 45(6):789-805. DOI: 10.1007/s00134-019-05599-w. View

Bloos F, Held J, Kluge S, Simon P, Kogelmann K, de Heer G . (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med. 2022; 48(7):865-875. PMC: 9273538. DOI: 10.1007/s00134-022-06733-x. View

10.

Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl J, Francais A . Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med. 2012; 40(3):813-22. DOI: 10.1097/CCM.0b013e318236f297. View

11.

Tissot F, Lamoth F, Hauser P, Orasch C, Fluckiger U, Siegemund M . β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013; 188(9):1100-9. DOI: 10.1164/rccm.201211-2069OC. View

12.

Rouze A, Loridant S, Poissy J, Dervaux B, Sendid B, Cornu M . Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med. 2017; 43(11):1668-1677. DOI: 10.1007/s00134-017-4932-8. View